首页|高压氧联合抗心衰治疗对扩张型心肌病合并心衰患者心脏功能储备及NT-proBNP表达的影响

高压氧联合抗心衰治疗对扩张型心肌病合并心衰患者心脏功能储备及NT-proBNP表达的影响

扫码查看
目的 探讨高压氧联合抗心衰治疗对扩张型心肌病(扩心病)合并心功能衰竭(心衰)患者心脏功能储备及N-末端脑钠肽前体(NT-proBNP)表达的影响.方法 选取2022年1月至2023年6月郑州市第七人民医院收治的100例扩心病合并心衰患者作为研究对象,按照随机数字表法分为观察组和对照组,每组50例.对照组患者给予贝那普利、酚妥拉明治疗,观察组在对照组的基础上联合高压氧治疗.采用超声心动图和心音图运动试验检测患者的心脏储备功能[心力储备指数(CCRI)、心脏储备指数(CRI)、6min步行距离],采用肺功能仪检测患者的肺功能[第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、峰值呼吸流速(PEF)],采用酶联免疫吸附法检测患者血清NT-proBNP水平,采用日立7600全自动生化仪检测患者血清肌钙蛋白Ⅰ(cTnI)水平,采用免疫比浊法测定患者血清超敏C反应蛋白(hs-CRP)水平.比较2组患者的临床疗效,治疗前后2组患者的心脏储备功能、肺功能及血清NT-proBNP、cTnI、hs-CRP的表达水平.结果 观察组患者治疗总有效率(94.00%)明显高于对照组(78.00%),差异有统计学意义(P<0.05).与治疗前比较,治疗后2组患者的心脏储备功能均升高,且观察组均高于对照组(P<0.05);肺功能指标均升高,且观察组均高于对照组(P<0.05);血清NT-proBNP、cTnI、hs-CRP水平均降低,且观察组均低于对照组(P<0.05).结论 高压氧联合抗心衰治疗扩心病合并心衰患者疗效较好,可有效改善患者的心脏储备功能、肺功能,调节血清NT-proBNP、cTnI、hs-CRP水平,值得临床推广运用.
Effects of hyperbaric oxygen combined with anti-heart failure treatment on cardiac function reserve and NT-proBNP expression in patients with dilated cardiomyopathy complicated with heart failure
Objective To investigate the effect of hyperbaric oxygen combined with anti-heart failure therapy on cardiac function reserve and N-terminal pro brain natriuretic peptide(NT-proNBP)expression in patients with dilated cardiomyopathy complicated with heart failure.Methods A total of 100 patients with dilated cardiomyopathy complicated with heart failure admitted to the Seventh People's Hospital of Zhengzhou from January 2022 to June 2024 were selected as the research subjects,who were randomly divided into observation group and control group using the random number table method,with 50 patients in each group.The control group patients were treated with benazepril and phentolamine,while the observation group received hyperbaric oxygen therapy in addition to the treatment of the control group.Echocardiography and phonocardiogram exercise tests were used to assess the cardiac reserve function[Cardiac contractility reserve index(CCRI),cardiac reserve index(CRI),6-minute walking distance].Pulmonary function tests were performed using a pulmonary function analyzer to measure the forced expiratory volume in one second(FEV1),FEV1/FVC(forced vital capacity),and peak expiratory flow rate(PEF).Enzyme linked immunosorbent assay was used to measure the serum NT-proBNP level.Hitachi 7600 fully automated biochemical analyzer was used to measure the serum cardiac troponin Ⅰ(cTnI)level,and immunoturbidimetry was used to measure the serum high-sensitivity C-reactive protein(hs-CRP)level.The clinical efficacy of two groups,as well as cardiac reserve function,pulmonary function,and serum NT-proBNP,cTnI,and hs-CRP expression levels before and after treatment,were compared.Results The total effective rate of treatment in the observation group(94.00%)was significantly higher than that in the control group(78.00%),and the difference was statistically significant(P<0.05).Compared with before treatment,the cardiac reserve function of both groups increased after treatment,and those indexes in the observation group were higher than those in the control group(P<0.05);the pulmonary function indexes all increased,and those indicators in the observation group were higher than those in the control group(P<0.05);the levels of serum NT-proBNP,cTnI,and hs-CRP were all reduced,and those indexes in the observation group were lower than those in the control group(P<0.05).Conclusion Hyperbaric oxygen combined with anti-heart failure therapy has a good therapeutic effect on patients with dilated cardiomyopathy complicated with heart failure,which can effectively improve the patient's cardiac reserve function and pulmonary function,regulate the levels of serum NT-proBNP,cTnI,and hs-CRP,and therefore it is worthy of clinical promotion and application.

Dilated cardiomyopathyHeart failureHyperbaric oxygenPulmonary functionCardiac function reserveN-terminal pro brain natriuretic peptide

张东东、杨龙、王晓英、刘春明、李攀攀

展开 >

郑州市第七人民医院心外科,郑州 450000

郑州市第七人民医院心内科,郑州 450000

郑州市第七人民医院高压氧治疗中心,郑州 450000

扩张型心肌病 心功能衰竭 高压氧 肺功能 心脏功能储备 N-末端脑钠肽前体

2024

中华航海医学与高气压医学杂志
中华医学会

中华航海医学与高气压医学杂志

CSTPCD
影响因子:0.57
ISSN:1009-6906
年,卷(期):2024.31(6)